Abstract

Cipla is one of India’s top five pharmaceutical manufacturers. Although Cipla’s primary market is India, the company sells its products worldwide. Cipla’s line of more than 400 drugs include anti-asthmatic, anti-cancer, anti-inflammatory, anti-depressant and anti-AIDS medications. Over the years, the company has developed strong research and marketing capabilities. In recent times, Cipla has attracted considerable media attention because of its efforts to offer AIDS drugs globally at very low prices. But in its quest to capture this market, Cipla faces the might of global multinational corporations, who are doing all they can to protect and enforce their patent rights. The case deals with all these issues in detail.

Learning Objectives

The case is structured to achieve the following Learning Objectives:

• 0

Keywords

Cipla, Indian pharmaceutical industry, Anti AIDS medicines, HIV drugs, Biotech products, Khwaja Abdul Hamied, Generic pharmaceutical business, Food and Drug Administration, World Health Organisation (WHO), US generic market, Globalisation, Avestha Gengraine Technologies, Morton Grove Pharmaceuticals